Lee Gi-won, CEO of Ybrain, is presenting on transcranial direct current stimulation (tDCS), the technology behind the electronic medicine for depression, MindStim, at the 2022 Neuroergonomics and NYC Neuromodulation Conference held in New York, USA.
[Asia Economy Reporter Chunhee Lee] Electronic medicine platform company Ybrain announced on the 22nd that it received the Translational Research Award for neuromodulation technology using transcranial direct current stimulation (tDCS) at the 2022 Neuroergonomics and NYC Neuromodulation Conference held earlier this month in New York, USA.
The Translational Research Award is a prestigious award in the field of neuromodulation, given to only two individuals each year who have made significant contributions to the field through remarkable research achievements among dozens of distinguished scholars nominated.
The Neuroergonomics and NYC Neuromodulation Conference introduces extensive knowledge on the latest neuroscience technologies that help improve brain-body functions and health. This year’s conference covered the latest technologies addressing brain function and dysfunction related to depression, stress and fatigue, pain, addiction and binge eating, cognitive and physical recovery, eye tracking, neuromarketing, and remote/mobile sensing.
The technology for which Ybrain received the award is tDCS (transcranial direct current stimulation), a technique that modulates nerves using microcurrents. It has been applied in the treatment of major depressive disorder. Ybrain launched Mindsteem, an electronic medicine for home treatment of depression incorporating tDCS, in South Korea as a non-reimbursed product in June.
The company analyzed that the selection of Ybrain’s technology at this year’s conference awards reflects the consideration of fast and effective depression treatment methods through home care in the pandemic environment, as depression cases surged worldwide due to the COVID-19 pandemic.
Lee Gi-won, CEO of Ybrain, said, “Building on this award, we plan to accelerate the launch of Mindsteem in the U.S. market so that American patients with depression can also be effectively treated with home-use electronic medicine for depression.” He added, “Through this conference, we received attention from various academic and corporate sectors and engaged in discussions about future collaborations.”
Meanwhile, Ybrain is currently submitting data and awaiting responses for the De Novo approval from the U.S. Food and Drug Administration (FDA) for Mindsteem. The company aims to complete clinical trials for electronic medicine for dementia within this year and obtain approval from the Ministry of Food and Drug Safety next year. Exploratory clinical trials for electronic medicine for insomnia and confirmatory clinical trials for mild cognitive impairment (MCI) are also planned. Having recently received an A grade from two institutions in the KOSDAQ listing technology evaluation, Ybrain plans to file a preliminary review for KOSDAQ listing within this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
